Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke. | Eur J Pharmacol;401(3): 419-28, 2000 Aug 11. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke.

Campbell, C A; Barone, F C; Benham, C D; Hadingham, S J; Harries, M H; Harling, J D; Hills, J M; Lewis, V A; Mackay, K B; Orlek, B S; White, R F; Parsons, A A; Hunter, A J.

Affiliation

Campbell CA; Neuroscience Research, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, Essex, UK. colin_a_campbell@sbphrd.com

Eur J Pharmacol ; 401(3): 419-28, 2000 Aug 11.

Article in En | MEDLINE | ID: mdl-10936502

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Calcium Channel Blockers / Neuroprotective Agents / Stroke / Sodium Channel Blockers / Indans Language: En Journal: Eur J Pharmacol Year: 2000 Document type: Article Affiliation country: Reino Unido Country of publication: Países Bajos

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Calcium Channel Blockers / Neuroprotective Agents / Stroke / Sodium Channel Blockers / Indans Language: En Journal: Eur J Pharmacol Year: 2000 Document type: Article Affiliation country: Reino Unido Country of publication: Países Bajos